ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,370 GBX | +0.31% |
|
+2.66% | +16.70% |
| 05-12 | Pfizer and AstraZeneca announce new investments of nearly $1 billion in France | RE |
| 05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
ETFs positioned on AstraZeneca PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 0 M€ | +16.95% | ||
| 5.17% | 0 M€ | +6.46% | - | |
| 4.89% | 0 M€ | +12.94% | ||
| 4.11% | 88 M€ | +10.37% | - | |
| 3.47% | 0 M€ | +13.20% | ||
| 2.74% | 4 M€ | -.--% | - | |
| 2.57% | 6 M€ | -.--% | ||
| 2.53% | 0 M€ | +7.65% | - | |
| 2.53% | 0 M€ | +10.93% | ||
| 1.54% | 29 M€ | +8.37% | - | |
| 1.51% | 2 M€ | -.--% | - | |
| 1.51% | 2 M€ | +9.19% | - | |
| 1.26% | 12 M€ | +15.09% | - | |
| 1.19% | 0 M€ | +9.46% | ||
| 1.16% | 10 M€ | -3.35% | - | |
| 0.97% | 0 M€ | +4.81% | - | |
| 0.89% | 0 M€ | +7.24% | - | |
| 0.86% | 276 M€ | +11.40% | - | |
| 0.70% | 0 M€ | -.--% | - | |
| 0.69% | 0 M€ | +9.15% | - | |
| 0.69% | 0 M€ | +11.72% | ||
| 0.57% | 205 M€ | -.--% | ||
| 0.54% | 284 M€ | -.--% | ||
| 0.51% | 23 M€ | -.--% | - | |
| 0.51% | 786 M€ | -.--% | ||
| 0.50% | 206 M€ | -.--% | ||
| 0.48% | 0 M€ | +8.33% | ||
| 0.43% | 0 M€ | +18.97% |
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
154.8
USD
Average target price
166.5
USD
Spread / Average Target
+7.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.70% | 240B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC
